Published in J Clin Endocrinol Metab on August 01, 2003
β-cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care (2012) 1.66
Type II diabetes mellitus and cardiovascular risk factors: Current therapeutic approaches. Exp Clin Cardiol (2007) 1.15
Assessment of pancreatic β-cell function: review of methods and clinical applications. Curr Diabetes Rev (2014) 0.94
Molecular mechanism by which pioglitazone preserves pancreatic beta-cells in obese diabetic mice: evidence for acute and chronic actions as a PPARgamma agonist. Am J Physiol Endocrinol Metab (2009) 0.94
The role of peroxisome proliferator-activated receptor γ in pancreatic β cell function and survival: therapeutic implications for the treatment of type 2 diabetes mellitus. Diabetes Obes Metab (2010) 0.93
Redefining the role of thiazolidinediones in the management of type 2 diabetes. Vasc Health Risk Manag (2009) 0.91
Pulsatile insulin secretion, impaired glucose tolerance and type 2 diabetes. Mol Aspects Med (2015) 0.91
Insulin as a Bridge between Type 2 Diabetes and Alzheimer Disease - How Anti-Diabetics Could be a Solution for Dementia. Front Endocrinol (Lausanne) (2014) 0.87
Management of type 2 diabetes mellitus. Role of thiazolidinediones. Can Fam Physician (2005) 0.86
Calcineurin inhibitors acutely improve insulin sensitivity without affecting insulin secretion in healthy human volunteers. Br J Clin Pharmacol (2012) 0.85
Inhibition of human insulin gene transcription by peroxisome proliferator-activated receptor gamma and thiazolidinedione oral antidiabetic drugs. Br J Pharmacol (2009) 0.83
Delayed β-cell response and glucose intolerance in young women with Turner syndrome. BMC Endocr Disord (2011) 0.80
The effect of pioglitazone on circulating interleukin-10 and tumor necrosis factor-alpha levels in a patient with metabolic syndrome: A randomized, double-blind controlled trial. ARYA Atheroscler (2015) 0.80
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46
Resequencing of 200 human exomes identifies an excess of low-frequency non-synonymous coding variants. Nat Genet (2010) 5.44
Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38
Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care (2007) 2.92
Glucagon-like peptide-1: regulation of insulin secretion and therapeutic potential. Basic Clin Pharmacol Toxicol (2004) 1.73
Long-term AICAR administration and exercise prevents diabetes in ZDF rats. Diabetes (2005) 1.71
Meal and oral glucose tests for assessment of beta -cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab (2002) 1.71
Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes (2002) 1.69
Pulsatile insulin secretion: detection, regulation, and role in diabetes. Diabetes (2002) 1.68
Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions. Diabetes Care (2007) 1.57
Evaluation of iterative reconstruction (OSEM) versus filtered back-projection for the assessment of myocardial glucose uptake and myocardial perfusion using dynamic PET. Eur J Nucl Med Mol Imaging (2006) 1.53
Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes (2002) 1.46
[Postprandial hyperglycemia. Postprandial blood glucose fluctuations, cardiovascular disease and late diabetic complications]. Ugeskr Laeger (2003) 1.39
Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes (2004) 1.37
Impact of exercise training on insulin sensitivity, physical fitness, and muscle oxidative capacity in first-degree relatives of type 2 diabetic patients. Am J Physiol Endocrinol Metab (2005) 1.29
Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. Am J Physiol Heart Circ Physiol (2010) 1.18
Effects of AICAR and exercise on insulin-stimulated glucose uptake, signaling, and GLUT-4 content in rat muscles. J Appl Physiol (1985) (2002) 1.16
Basal and insulin mediated VLDL-triglyceride kinetics in type 2 diabetic men. Diabetes (2010) 1.07
Measurements of insulin responses as predictive markers of pancreatic beta-cell mass in normal and beta-cell-reduced lean and obese Göttingen minipigs in vivo. Am J Physiol Endocrinol Metab (2005) 1.07
Evidence of a relationship between infant birth weight and later diabetes and impaired glucose regulation in a Chinese population. Diabetes Care (2007) 1.06
Acute effects of ghrelin administration on glucose and lipid metabolism. J Clin Endocrinol Metab (2007) 1.05
Metformin induces cardioprotection against ischaemia/reperfusion injury in the rat heart 24 hours after administration. Basic Clin Pharmacol Toxicol (2008) 0.99
Evidence of increased visceral obesity and reduced physical fitness in healthy insulin-resistant first-degree relatives of type 2 diabetic patients. Eur J Endocrinol (2004) 0.99
SLC30A3 responds to glucose- and zinc variations in beta-cells and is critical for insulin production and in vivo glucose-metabolism during beta-cell stress. PLoS One (2009) 0.99
Effect of short-term intralipid infusion on the immune response during low-dose endotoxemia in humans. Am J Physiol Endocrinol Metab (2007) 0.98
Effects of cortisol on carbohydrate, lipid, and protein metabolism: studies of acute cortisol withdrawal in adrenocortical failure. J Clin Endocrinol Metab (2007) 0.98
Studies of the common DIO2 Thr92Ala polymorphism and metabolic phenotypes in 7342 Danish white subjects. J Clin Endocrinol Metab (2006) 0.98
Zinc-transporter genes in human visceral and subcutaneous adipocytes: lean versus obese. Mol Cell Endocrinol (2006) 0.96
Zinc transporter gene expression is regulated by pro-inflammatory cytokines: a potential role for zinc transporters in beta-cell apoptosis? BMC Endocr Disord (2009) 0.94
Impaired basal glucose effectiveness but unaltered fasting glucose release and gluconeogenesis during short-term hypercortisolemia in healthy subjects. Am J Physiol Endocrinol Metab (2003) 0.94
Preferential stimulation of abdominal subcutaneous lipolysis after prednisolone exposure in humans. Obes Res (2002) 0.93
Energy expenditure, insulin, and VLDL-triglyceride production in humans. J Lipid Res (2006) 0.93
Endothelial function and biochemical vascular markers in first-degree relatives of type 2 diabetic patients: the effect of exercise training. Metabolism (2006) 0.92
Short-term changes in circulating insulin and free fatty acids affect Nt-pro-BNP levels in heart failure patients. Int J Cardiol (2009) 0.92
Effects of GH on urea, glucose and lipid metabolism, and insulin sensitivity during fasting in GH-deficient patients. Am J Physiol Endocrinol Metab (2003) 0.92
The -250G>A promoter variant in hepatic lipase associates with elevated fasting serum high-density lipoprotein cholesterol modulated by interaction with physical activity in a study of 16,156 Danish subjects. J Clin Endocrinol Metab (2008) 0.91
Association of variants in the sterol regulatory element-binding factor 1 (SREBF1) gene with type 2 diabetes, glycemia, and insulin resistance: a study of 15,734 Danish subjects. Diabetes (2008) 0.91
Acute hyperinsulinemia restrains endotoxin-induced systemic inflammatory response: an experimental study in a porcine model. Anesthesiology (2004) 0.89
Glucagon-like peptide-1 inhibits blood-brain glucose transfer in humans. Diabetes (2007) 0.88
Role of nonalcoholic fatty liver disease in the development of insulin resistance and diabetes. Expert Rev Gastroenterol Hepatol (2008) 0.88
Mathematical models of diabetes progression. Am J Physiol Endocrinol Metab (2008) 0.88
Evidence against a role for insulin-signaling proteins PI 3-kinase and Akt in insulin resistance in human skeletal muscle induced by short-term GH infusion. Am J Physiol Endocrinol Metab (2004) 0.88
Suppression of circulating free fatty acids with acipimox in chronic heart failure patients changes whole body metabolism but does not affect cardiac function. Am J Physiol Heart Circ Physiol (2010) 0.88
The effect of exercise, training, and inactivity on insulin sensitivity in diabetics and their relatives: what is new? Appl Physiol Nutr Metab (2007) 0.87
Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study. Diabetes Metab Res Rev (2009) 0.86
Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19). J Clin Endocrinol Metab (2010) 0.86
Effects of fasting on physiologically pulsatile insulin release in healthy humans. Diabetes (2002) 0.85
The insulin secretagogues glibenclamide and repaglinide do not influence growth hormone secretion in humans but stimulate glucagon secretion during profound insulin deficiency. J Clin Endocrinol Metab (2004) 0.85
The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. J Clin Endocrinol Metab (2007) 0.85
Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria. Diabetes Care (2007) 0.84
Impaired insulin action despite upregulation of proximal insulin signaling: novel insights into skeletal muscle insulin resistance in liver cirrhosis. J Hepatol (2006) 0.83
Contribution of defects in glucose uptake to carbohydrate intolerance in liver cirrhosis: assessment during physiological glucose and insulin concentrations. Am J Physiol Gastrointest Liver Physiol (2005) 0.82
Exercise and fasting activate growth hormone-dependent myocellular signal transducer and activator of transcription-5b phosphorylation and insulin-like growth factor-I messenger ribonucleic acid expression in humans. J Clin Endocrinol Metab (2010) 0.81
Human insulin release processes measured by intraportal sampling. Am J Physiol Endocrinol Metab (2002) 0.81
Delayed β-cell response and glucose intolerance in young women with Turner syndrome. BMC Endocr Disord (2011) 0.80
Characterization of beta-cell function impairment in first-degree relatives of type 2 diabetic subjects: modeling analysis of 24-h triple-meal tests. Am J Physiol Endocrinol Metab (2004) 0.80
High prevalence of impaired glucose homeostasis and myopathy in asymptomatic and oligosymptomatic 3243A>G mitochondrial DNA mutation-positive subjects. J Clin Endocrinol Metab (2009) 0.80
Response of retinal arteriole diameter to increased blood pressure during acute hyperglycaemia. Acta Ophthalmol Scand (2007) 0.80
Free fatty acids inhibit growth hormone/signal transducer and activator of transcription-5 signaling in human muscle: a potential feedback mechanism. J Clin Endocrinol Metab (2009) 0.80
Treatment with an SSRI antidepressant restores hippocampo-hypothalamic corticosteroid feedback and reverses insulin resistance in low-birth-weight rats. Am J Physiol Endocrinol Metab (2010) 0.80
Microarray expression analysis in delayed cardioprotection: the effect of exercise, AICAR, or metformin and the possible role of AMP-activated protein kinase (AMPK). Mol Cell Biochem (2011) 0.79
Peroxisome proliferator-activated receptor gamma agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity. Clin Endocrinol (Oxf) (2008) 0.77
5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside increases myocardial glucose uptake during reperfusion and induces late pre-conditioning: potential role of AMP-activated protein kinase. Basic Clin Pharmacol Toxicol (2009) 0.77
Evaluation of the relationship between hyperinsulinaemia and myocardial ischaemia/reperfusion injury in a rat model of depression. Clin Sci (Lond) (2009) 0.77
Muscle GLUT4 in cirrhosis. J Hepatol (2007) 0.77
Impact of type 2 diabetes on myocardial insulin sensitivity to glucose uptake and perfusion in patients with coronary artery disease. J Clin Endocrinol Metab (2006) 0.77
Is metformin therapy for polycystic ovary syndrome safe during pregnancy? Basic Clin Pharmacol Toxicol (2005) 0.77
New strategies in insulin treatment: analogues and noninvasive routes of administration. Fundam Clin Pharmacol (2005) 0.76
Angiotensin II inhibition increases cellular glucose transport during reperfusion but not ischemia in pig hearts. Scand Cardiovasc J (2003) 0.76
Increased action of pulsatile compared to non-pulsatile insulin delivery during a meal-like glucose exposure simulated by computerized infusion in healthy humans. Metabolism (2012) 0.76
Acute hyperinsulinemia increases the contraction of retinal arterioles induced by elevated blood pressure. Am J Physiol Heart Circ Physiol (2013) 0.75
Insulin sensitivity and body composition in cirrhosis: changes after TIPS. Am J Physiol Gastrointest Liver Physiol (2010) 0.75
The GLP-1 concept in the treatment of type 2 diabetes--still standing at the gate of dawn? J Clin Endocrinol Metab (2008) 0.75
Insulin-stimulated myocardial glucose uptake and the relation to perfusion and the nitric oxide system. J Vasc Res (2004) 0.75
[Coffee and diabetes--something to be really concerned about?]. Ugeskr Laeger (2002) 0.75
The circulating IGF system and its relationship with 24-h glucose regulation and insulin sensitivity in healthy subjects. Clin Endocrinol (Oxf) (2003) 0.75
Impact of type 2 diabetes on nitric oxide and adrenergic modulation of myocardial perfusion. Diabetes (2007) 0.75